

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 8-K

BIOMARIN PHARMACEUTICAL INC

Form 8-K

December 23, 2002

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 20, 2002

BioMarin Pharmaceutical Inc.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation or organization)	000-26727 (Commission File Number)	68-0397820 (IRS Employer Identification No.)
---	--	--

371 Bel Marin Keys Boulevard, Suite 210, Novato, California (Address of principal executive offices)	94949 (Zip Code)
---	---------------------

Registrant's telephone number, including area code: (415) 884-6700

Not Applicable

(Former name or former address, if changed since last report)

Item 5. Other Events.

On December 20, 2002, BioMarin Pharmaceutical Inc. (the "Registrant") issued a press release regarding the filing of a registration statement with the Securities and Exchange Commission for the offer and sale by the Registrant of up to an aggregate of \$150 million of its common stock. The Registrant's press release issued on December 20, 2002 is attached hereto as Exhibit 99.1.

Item 7. Financial Statements, Pro Forma Financial Statements and Exhibits.

(a) Financial Statements of Business Acquired.

Not Applicable.

(b) Pro Forma Financial Information.

Not Applicable.

(c) Exhibits.

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 8-K

Exhibit 99.1 Press Release of the Registrant dated December 20, 2002.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BioMarin Pharmaceutical Inc.,  
a Delaware corporation

Date: December 20, 2002

By: /s/ Louis Drapeau

-----

Louis Drapeau  
Chief Financial Officer, Vice President,  
Finance and Secretary

EXHIBIT INDEX

Exhibit No. -----	Description -----
Exhibit 99.1	Press Release of the Registrant dated December 20, 2002.